← Back to Search

Treatment for Alzheimer's Disease (REPHRASE Trial)

N/A
Waitlist Available
Led By Charles Bernick, MD, MPH
Research Sponsored by Optina Diagnostics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This observational, cross-sectional study is designed to validate a novel diagnostic test for the detection of phenotypic changes in the retina that correlate with likely PET amyloid status (negative or positive), to aid in the evaluation of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The CAS test is an adjunct to other diagnostic evaluations, and is indicated for use with the Optina Diagnostics' MHRC (K200254).

Eligible Conditions
  • Alzheimer's Disease
  • Mild Cognitive Impairment

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Retinal beta-amyloid detection

Find a Location

Who is running the clinical trial?

The Cleveland ClinicOTHER
1,045 Previous Clinical Trials
1,370,209 Total Patients Enrolled
Sunnybrook Research InstituteOTHER
31 Previous Clinical Trials
215,319 Total Patients Enrolled
Cleveland Clinic Lou Ruvo Center for BrainUNKNOWN
~143 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top